García-Ramos, R., García Pastor, A., Masjuan, J., Sánchez, C., & Gil, A. (2011). FEEN report on epilepsy in Spain. Neurología (English Edition), 26(9), 548-555. doi:10.1016/j.nrleng.2011.03.004
Epilepsy http://www.who.int/mediacentre/factsheets/fs999/en/
Población Estimada en España http://www.ine.es/inebaseDYN/cp30321
[+]
García-Ramos, R., García Pastor, A., Masjuan, J., Sánchez, C., & Gil, A. (2011). FEEN report on epilepsy in Spain. Neurología (English Edition), 26(9), 548-555. doi:10.1016/j.nrleng.2011.03.004
Epilepsy http://www.who.int/mediacentre/factsheets/fs999/en/
Población Estimada en España http://www.ine.es/inebaseDYN/cp30321
Duncan, J. S., Sander, J. W., Sisodiya, S. M., & Walker, M. C. (2006). Adult epilepsy. The Lancet, 367(9516), 1087-1100. doi:10.1016/s0140-6736(06)68477-8
Brodie, M. J. (2015). Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy. CNS Drugs, 29(11), 893-904. doi:10.1007/s40263-015-0285-4
EPARs for Authorised Medicinal Products for Human Use Stelara http://www.emea.europa.eu/humandocs/Humans/EPAR/stelara/stelara.htm
Kristian, B., Wachtmeister, K., Stefan, F., & Forsgren, L. (2013). Retigabine as add-on treatment of refractory epilepsy - a cost-utility study in a Swedish setting. Acta Neurologica Scandinavica, 127(6), 419-426. doi:10.1111/ane.12077
Martyn-St James, M., Glanville, J., McCool, R., Duffy, S., Cooper, J., Hugel, P., & Lane, P. W. (2012). The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: A systematic review and indirect comparison. Seizure, 21(9), 665-678. doi:10.1016/j.seizure.2012.07.011
Cortés, J.-C., Navarro-Quiles, A., Romero, J.-V., & Roselló, M.-D. (2017). Randomizing the parameters of a Markov chain to model the stroke disease: A technical generalization of established computational methodologies towards improving real applications. Journal of Computational and Applied Mathematics, 324, 225-240. doi:10.1016/j.cam.2017.04.040
Sonnenberg, F. A., & Beck, J. R. (1993). Markov Models in Medical Decision Making. Medical Decision Making, 13(4), 322-338. doi:10.1177/0272989x9301300409
Barrachina-Martínez, I., Vivas-Consuelo, D., & Piera-Balbastre, A. (2017). Budget Impact Analysis of Brivaracetam Adjunctive Therapy for Partial-Onset Epileptic Seizures in Valencia Community, Spain. Clinical Drug Investigation, 38(4), 353-363. doi:10.1007/s40261-017-0615-z
Sullivan, S. D., Mauskopf, J. A., Augustovski, F., Jaime Caro, J., Lee, K. M., Minchin, M., … Shau, W.-Y. (2014). Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health, 17(1), 5-14. doi:10.1016/j.jval.2013.08.2291
Cortés, J.-C., Navarro-Quiles, A., Romero, J.-V., & Roselló, M.-D. (2018). Some results about randomized binary Markov chains: theory, computing and applications. International Journal of Computer Mathematics, 97(1-2), 141-156. doi:10.1080/00207160.2018.1440290
Prieto, L., Sacristán, J. A., Antoñanzas, F., Rubio-Terrés, C., Pinto, J. L., & Rovira, J. (2004). Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias. Medicina Clínica, 122(13), 505-510. doi:10.1016/s0025-7753(04)74288-8
Karlsson, G., & Johannesson, M. (1996). The Decision Rules of Cost-Effectiveness Analysis. PharmacoEconomics, 9(2), 113-120. doi:10.2165/00019053-199609020-00003
Mulhern, B., Rowen, D., Snape, D., Jacoby, A., Marson, T., Hughes, D., … Brazier, J. (2014). Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population. Epilepsy & Behavior, 36, 12-17. doi:10.1016/j.yebeh.2014.04.011
BOT Base de Datos del Medicamento https://botplusweb.portalfarma.com/
Informe de Posicionamiento Terapéutico de Brivaracetam (Briviact) en Epilepsia https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPTbrivaracetam-Briviact-epilepsia.pdf
Sacristán, J. A., Oliva, J., Del Llano, J., Prieto, L., & Pinto, J. L. (2002). ¿Qué es una tecnología sanitaria eficiente en España? Gaceta Sanitaria, 16(4), 334-343. doi:10.1016/s0213-9111(02)71933-x
Bertram, M. Y., Lauer, J. A., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M.-P., & Hill, S. R. (2016). Cost–effectiveness thresholds: pros and cons. Bulletin of the World Health Organization, 94(12), 925-930. doi:10.2471/blt.15.164418
[-]